Ani pharmaceuticals inc (ANIP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows From Operating Activities
Net (loss)/Income

-7,011

-4,835

3,895

6,585

449

5,430

5,037

2,777

2,250

-9,629

4,720

2,681

1,152

-1,080

2,543

1,125

1,346

2,876

4,559

3,571

4,369

21,005

6,746

-2,363

3,359

3,433

1,191

-4,583

260

-

-

-

-10,264

-6,648

-12,733

-14,975

-17,250

Adjustments to reconcile net loss to net cash and cash equivalents provided by operating activities:
Stock-based compensation

2,424

2,444

2,470

2,593

1,710

1,828

1,795

1,782

1,377

1,422

1,475

1,807

1,386

1,380

1,365

2,217

1,105

1,139

1,120

1,029

568

704

693

1,979

47

33

3

0

0

-

-

-

313

291

305

281

300

Deferred taxes

-19,243

-2,701

-3,728

-2,540

-165

-2,599

-1,594

-491

-496

8,162

-2,896

-971

-735

-7,827

-649

-354

-81

-1,932

-358

119

294

-14,459

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

11,183

9,564

9,473

9,472

16,103

8,686

8,548

8,313

8,195

7,022

7,099

7,101

6,706

5,812

5,966

5,956

4,609

2,111

2,047

1,415

1,327

1,282

1,187

706

703

437

382

146

145

141

143

250

30

30

35

40

41

Acquired in-process research and development ("IPR&D")

3,753

-329

329

2,324

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock warrant expense - noncash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

28

102

50

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-0

-365

0

-2

Non-cash interest relating to convertible notes and loan cost amortization

182

1,345

1,913

1,893

1,873

2,073

2,155

2,130

2,107

1,943

1,933

1,908

1,882

1,860

1,939

1,757

1,725

1,696

1,747

1,705

1,683

559

0

0

0

434

0

-195

-22

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

10,250

1,429

-5,574

8,864

2,568

-2,805

10,221

1,314

-3,987

-3,386

6,661

8,816

802

-1,582

11,915

13,081

549

287

2,765

1,509

74

2,727

6,776

-3,113

-1,606

2,998

3,088

523

472

-

-

-

-

-

-

-

-

Inventories, net

-3,693

1,989

878

3,264

1,529

497

53

3,262

-3,433

-751

-3,829

-3,586

2,810

-2,078

3,209

272

535

-354

1,040

1,964

3,219

172

902

822

1,572

709

224

-453

228

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-1,028

-913

1,714

-846

-358

-627

2,875

-576

-530

-1,348

2,201

-861

25

24

-1,369

2,193

-201

312

370

69

-437

539

106

-73

-14

0

329

-63

-78

171

-53

54

-84

-142

-69

-137

-1,332

Accounts payable

-1,332

2,909

798

-673

2,005

1,216

-2,321

2,866

1,705

-2,075

2,423

-1,663

1,318

-1,486

-288

1,961

889

-897

1,249

-908

-471

-405

328

-996

1,298

-658

452

-459

100

-

-

-

-

-

-

-

-

Accrued royalties

1,201

-443

-738

825

-3,016

1,001

-764

-3,142

-803

423

-139

1,549

-2,250

187

3,659

-404

2,827

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation and related expenses

-

-

-

-

-

-

-

-

-

-

782

92

-496

-

355

349

-466

169

175

331

-835

615

41

226

-307

-

-

-

-

-

-

-

-

-

-

-

-

Current income taxes, net

16,299

-262

2,628

-6,895

-1,569

4,704

2,052

-1,672

1,100

890

1,939

-7,647

1,258

3,327

-779

1,000

-23

-155

50

-1,503

-3,772

3,109

1,121

-32

35

-

-

-

-

-

-

-

-

-

-

-

-

Accrued government rebates

-871

-283

-1,759

2,391

-422

-40

3,758

-1,215

-1,459

2,175

2,221

-1,121

-1,236

-560

-58

3,085

-1,207

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Returned goods reserve

1,019

650

1,289

1,097

1,007

1,712

1,076

744

746

-43

759

1,782

20

1,657

790

643

18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses, accrued compensation, and other

-365

-826

2,241

-1,046

55

-182

1,726

-834

258

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued Medicaid rebates

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,537

-186

-187

-

1,079

-73

17

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

1,801

-1,148

1,161

-

-4

1,548

1,110

-1,881

1,576

-605

1,000

-630

748

143

-21

315

221

-464

-139

-

-

-

-

-

-

-

-

Convertible note fair value adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,210

1,905

463

-1,753

-639

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,063

-2,858

-190

-1,227

4,410

Net Cash and Cash Equivalents Provided by Operating Activities

1,710

4,803

21,793

4,744

14,291

27,232

8,319

8,593

22,930

15,805

17,084

1

6,529

12,082

1,084

3,337

10,969

-

-

-

-

10,741

4,159

1,954

5,179

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash and Cash Equivalents Provided by Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,236

1,206

1,120

-

-

-

-

-2,909

-1,392

-754

-234

-482

-118

8,295

-7,689

-10,925

-12,583

-13,888

-10,473

Acquisition of product rights, IPR&D, and other related assets

56,007

-329

409

2,324

18,510

0

0

5,169

0

46,668

0

0

50,956

0

0

60,312

84,182

0

26,000

0

4,500

0

22,117

0

12,517

0

0

0

0

-

-

-

-

-

-

-

-

Acquisition of property and equipment, net

1,539

1,703

1,523

1,634

1,775

1,007

1,372

1,086

2,278

3,447

2,480

2,304

2,138

1,389

1,089

719

1,369

1,105

768

198

112

338

411

253

118

29

34

20

108

215

7

14

54

74

102

321

221

Net Cash and Cash Equivalents Used in Investing Activities

-57,546

-1,374

-1,932

-3,958

-20,285

-407

-18,439

-6,255

-2,278

-50,115

-2,480

-2,304

-53,094

-1,389

-1,089

-61,031

-85,551

-1,105

-26,768

-198

-4,612

-338

-22,528

-253

-12,635

2,231

-34

18,178

-108

-215

-7

-6

-62

-74

-102

-321

-221

Purchase of investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

-

-

-

-

Cash Flows From Financing Activities
Borrowings under Revolver agreement

15,000

-

-

-

0

-

-

-

-

-

-5,000

0

30,000

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from equity offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-14

46,694

0

0

0

0

-

-

-

-

-

-

-

-

Payment of debt issuance costs

-

-

-

-

-

-

0

0

153

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on Term loan agreement

902

902

903

0

902

938

937

0

938

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of line of credit, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-4,437

372

-

-

-

-

-

-

-

-

Proceeds from stock option exercised

281

886

133

2,303

2,416

161

206

1,100

1,511

162

60

106

25

208

858

360

144

48

527

235

9

42

34

0

743

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from warrant exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

570

0

0

180

809

0

0

0

-

-

-

-

-

-

-

-

Excess tax benefit from share-based compensation awards

-

-

-

-

-

-

-

-

-

-

-

-

-

310

288

18

1

126

187

38

9

352

424

-99

107

0

0

0

0

-

-

-

-

-

-

-

-

Repurchase of common stock under the stock repurchase program

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Treasury stock purchases for restricted stock vests

488

0

0

723

308

0

0

409

250

0

0

259

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash and Cash Equivalents (Used in)/Provided by Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

636

170

7,684

-7,751

-12,374

32,474

-14,223

13,193

Proceeds from issuance of common stock by registered direct offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

17

-29

23,888

Net Cash and Cash Equivalents Provided by Financing Activities

13,891

-766

-770

1,580

1,206

-27,946

-731

691

170

47,425

-4,940

-153

30,025

518

1,146

-38

-2,355

174

714

160

18

123,584

458

-113

47,724

809

0

-4,870

372

-

-

-

-

-1,375

45,160

-13

23,888

Change in Cash, Cash Equivalents, and Restricted Cash

-41,945

2,663

19,091

2,366

-4,788

-1,121

-10,851

3,029

20,822

13,115

9,664

-2,456

-16,540

11,211

1,141

-57,732

-76,937

3,771

-15,818

1,168

-3,474

133,987

-17,911

1,588

40,268

175

-1,665

12,554

30

-

-

-

-

-

-

-

-

Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized

1,848

2,465

690

2,488

449

2,522

584

2,726

453

1,562

100

2,097

0

-

-

-

-

-

-

-

-

-

-

-

-

0

0

179

71

-

-

-

-

-

-

-

-

Cash paid for income taxes

95

140

1,170

8,723

0

-

-

-

-

5,293

2,611

9,878

4

3,690

3,641

563

1,643

2,587

1,218

3,421

6,029

10

77

0

60

0

0

0

0

-

-

-

-

-

-

-

-

Supplemental non-cash investing and financing activities:
Acquisition of product rights, IPRED and other related assets included in accounts payable

1,940

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued royalties related to asset purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,683

1,199

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment purchased and included in accounts payable

138

244

346

-37

170

411

-123

197

36

131

245

31

78

145

57

-40

85

330

59

-55

105

-

-

-

-

-

-

-

-

-

-

-

-

-37

20

0

38

Preferred stock dividends accrued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

2,370

2,604

-

-

-

-

-

-

-

-

Property and equipment purchased on credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued for convertible senior notes and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,132

-

-

-

-